Melanotan 1 vs Melanotan 2: the difference explained

Research context (RUO): Melanotan 1 and Melanotan 2 are synthetic analogues of the melanocyte-stimulating hormone (α-MSH) that engage the melanocortin receptors. Both peptides are supplied at Peplife exclusively for in-vitro laboratory research (Research Use Only) and are not intended for human or animal use.

Melanotan 1 vs Melanotan 2: the difference explained

The comparison Melanotan 1 vs melanotan 2 is one of the most common points of confusion in melanocortin research. The names resemble each other and both peptides act on the same hormone family, but pharmacologically they are two different molecules with a divergent receptor profile, a different research focus and a completely different regulatory status. Melanotan 1 (afamelanotide) is a linear, MC1R-selective peptide that has been approved as a drug; Melanotan 2 is a cyclic, non-selective analogue that is not approved anywhere. This pillar sets out the differences clearly side by side, strictly in a research context.

The core: one molecule, two design philosophies

Both peptides are derived from α-MSH, the body's own hormone that drives pigment production (melanogenesis) via the melanocortin-1 receptor (MC1R) on melanocytes. Natural α-MSH is rapidly broken down in the body and is not very potent. Researchers therefore built analogues that are more stable and more potent. This is where the two designs diverge:

• Melanotan 1 (afamelanotide): a linear 13-amino-acid peptide, chemically [Nle4, D-Phe7]-α-MSH. Two amino-acid substitutions make it resistant to degradation and increase the affinity, but the MC1R-selectivity is largely preserved.
• Melanotan 2: a cyclic, strongly shortened lactam heptapeptide. The ring structure makes the molecule compact and highly potent, but at the same time non-selective: it activates several melanocortin receptors simultaneously.

Receptor profile: MC1R-selective vs non-selective

The key difference in the melanotan 1 vs melanotan 2 discussion lies in which receptors are engaged. The melanocortin family has five receptors (MC1R through MC5R), spread across skin, brain, adrenal gland and other tissues, each with its own function.

• Melanotan 1 — predominantly MC1R: afamelanotide acts primarily as an agonist at the MC1R, the receptor that drives the switch from red-yellow pigment (pheomelanin) to brown-black pigment (eumelanin). Because the effect is largely directed at a single receptor, the research profile is relatively narrowly defined.
• Melanotan 2 — MC1R plus MC3R, MC4R, MC5R: because of its cyclic structure, Melanotan 2 is a non-selective agonist that, alongside MC1R, also activates the central receptors MC3R and MC4R and the MC5R. The MC4R activation in the brain is particularly research-relevant, because this receptor is involved in appetite, energy balance and sexual arousal.

Pigment vs libido: why the research objective differs

The divergent receptor profile explains why the two peptides are studied for different purposes.

• Melanotan 1 — pigment and photoprotection: because the effect on MC1R is concentrated, research into afamelanotide revolves almost entirely around melanogenesis and skin protection. In the clinical pathway that led to approval, afamelanotide was studied in erythropoietic protoporphyria (EPP), a rare condition with extreme light sensitivity; researchers reported that an increase in eumelanin enhanced phototolerance.
• Melanotan 2 — pigment plus central effects: because Melanotan 2 also engages the central MC3R/MC4R, it is associated in the literature with broader effects than pigmentation alone, including effects on appetite and on sexual response. The erectile and libido-related observations under MC4R activation were precisely what prompted the development of PT-141 (bremelanotide), a related melanocortin analogue that targets those central receptors more specifically.

In short: the narrower, MC1R-focused profile of Melanotan 1 makes it “cleaner” in the sense that the research revolves mainly around pigment, whereas the broader profile of Melanotan 2 brings both pigment and central (appetite/libido) effects into the research.

Regulatory status: approved vs not approved

This is the sharpest distinction between the two. Melanotan 1 (afamelanotide) is approved as a drug under the brand name Scenesse: registered by the European Medicines Agency (EMA) in 2014 and by the US FDA in 2019, for adults with erythropoietic protoporphyria. It is therefore a regulated, prescription implant within a strictly medical indication. Melanotan 2 is, by contrast, nowhere approved as a drug; regulators such as the EMA, FDA and NVWA have repeatedly warned against unregulated variants. For both peptides the same rule applies at Peplife: they are supplied exclusively as research material (RUO), independent of the medical status of afamelanotide.

Melanotan 1 and Melanotan 2 in laboratory research: handling & dissolving

Both peptides are supplied as freeze-dried (lyophilised) powder and must be reconstituted for in-vitro work, typically with bacteriostatic or sterile water. The cyclic Melanotan 2 and the linear Melanotan 1 differ in stability, but both are sensitive to light and repeated freeze-thaw cycles. See the pillar reconstitute peptides and which liquid for dissolving peptides for the common laboratory practice around preparation and storage.

Quality & purity

For a reliable melanotan 1 vs melanotan 2 comparison in the lab, identity and purity control is essential — precisely because the molecules are so similar yet behave differently. Every relevant batch is independently HPLC-tested by an external laboratory; the certificate of analysis (CoA) is publicly verifiable per batch, so the research material demonstrably matches the specified peptide. In the pillar why we rejected a batch you can read how that process works in practice.

Frequently asked questions about melanotan 1 vs melanotan 2

What is the key difference between melanotan 1 and melanotan 2?
Melanotan 1 (afamelanotide) is a linear, predominantly MC1R-selective peptide that has been approved as a drug; Melanotan 2 is a cyclic, non-selective analogue (MC1R/MC3R/MC4R/MC5R) that is not approved anywhere. The receptor profile determines the difference in research focus.

Why is Melanotan 2 associated with libido and Melanotan 1 not?
Melanotan 2 also activates the central MC4R receptor, which in research is associated with sexual arousal. Melanotan 1 is largely directed at MC1R (pigment) and barely engages those central receptors.

Is Melanotan 1 the same as afamelanotide or Scenesse?
Yes. Melanotan 1 is the research name for afamelanotide, which as a drug is called Scenesse and has been approved by the EMA (2014) and FDA (2019) for erythropoietic protoporphyria.

Is Melanotan 2 approved anywhere?
No. Melanotan 2 has not been approved as a drug by any regulator. At Peplife it is supplied exclusively as research material (RUO), not for human or animal use.

Are PT-141 and Melanotan 2 related?
Yes. PT-141 (bremelanotide) emerged from research into the melanocortin system and targets more specifically the central receptors associated with sexual response; it is discussed in the PT-141 research covered separately.

Which peptide is “better” for research?
That depends entirely on the research question: MC1R-selective pigment research aligns with Melanotan 1, while broader melanocortin research (including central effects) belongs with Melanotan 2. “Better” is not a meaningful comparison apart from the research objective.

Read more & research at Peplife

• Research Melanotan 1 at Peplife
• Research Melanotan 2 at Peplife
• View all skin peptides
• Melanotan 1: research into afamelanotide and MC1R
• Melanotan 2: research into the non-selective analogue
• PT-141 (bremelanotide): the melanocortin libido research
• Melanotan 2 vs PT-141

Sources: Langendonk et al., NEJM 2015 — Afamelanotide for Erythropoietic Protoporphyria · PubChem — Afamelanotide (CID 16197727) · PubChem — Melanotan II (CID 92432) · FDA — Scenesse (afamelanotide) approval documentation, 2019

Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.